HBK INVESTMENTS L P - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 2.47 and the average weighting 0.1%.

Quarter-by-quarter ownership
HBK INVESTMENTS L P ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2015$2,312,000
+14.9%
15,478
+82.1%
0.02%
-32.3%
Q3 2014$2,012,000
-69.7%
8,500
-69.8%
0.03%
-77.0%
Q2 2014$6,649,000
+41.0%
28,100
+96.5%
0.14%
+55.2%
Q1 2014$4,716,00014,3000.09%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2014
NameSharesValueWeighting ↓
Carmignac Gestion 2,028,192$229,389,0001.76%
Orbimed Advisors 1,037,000$117,285,0001.33%
BB BIOTECH AG 255,719$28,922,0000.95%
ALTRINSIC GLOBAL ADVISORS LLC 193,369$21,870,0000.74%
FALCON POINT CAPITAL, LLC 44,573$5,041,0000.67%
Rhenman & Partners Asset Management AB 30,000$3,393,0000.54%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 11,155$1,262,0000.48%
NATIONAL PLANNING CORP 52,400$5,888,0000.44%
HIGHFIELDS CAPITAL MANAGEMENT LP 364,232$41,195,0000.38%
SPHERA FUNDS MANAGEMENT LTD. 15,000$1,697,0000.33%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders